Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABBV 706

Next Previous
X
Search
Drug Profile

ABBV 706

Alternative Names: ABBV-706

Latest Information Update: 08 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 31 May 2024 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 28 May 2024 Efficacy and adverse events data from a phase I trial in Small cell lung cancer released by AbbVie
  • 05 Apr 2024 Adverse events and pharmacodynamics data from preclinical studies in Small cell lung cancer and other neuroendocrine tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top